Early safety and efficacy findings of auto1 (cat19), a fast-off rate cd19 car, in relapsed / refractory indolent b cell lymphomas
HemaSphere
; 5(SUPPL 2):361-362, 2021.
Article
in English
| EMBASE | ID: covidwho-1393454
ABSTRACT
Background:
We have previously described AUTO1 (CAT19), a CD19 CAR with a fast off-rate CD19 binding domain, designed to reduce CAR T-cell immune toxicity and improve engraftment. Its clinical activity has been tested in r/r paediatric and adult B-ALL. Cumulatively, this data confirms the intended fucntion of the receptor, with low levels of CRS/ ICANS and long-term engraftment of CAR T-cells observed in both patient groups. Recently, CAR therapy has been explored in indolent lymphomas such as follicluar (FL) and mantle cell lymphoma (MCL), but a high incidence of toxicity inluding Grade 3-4 ICANS has been reported.Aims:
We have initiated testing of AUTO1 (CAT19) in the setting of indolent B-cell lymphoma (NCT02935257).Methods:
Manufacturing CAR T-cell products were generated using a semi-automated closed process from non-mobilised leucapheresate. Studydesign:
subjects>/=16y underwent lymhpodepletion with fludarabine (30mg/m2 x3) and cyclophosphamide (60mg/kg x1) followed by a single CAR T-cell infusion of 200 x10
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
HemaSphere
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS